Personalized therapy for pazopanib

Not Applicable

• Conditions: Malignant soft tissue tumor Renal cell carcinoma

• Registration Number: JPRN-UMIN000021999
• Lead Sponsor: Department of pharmaceutical sciences, Tohoku university hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-04-20
• Study Completion: 2020-05-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

No

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To compare blood concentration, efficy and adverse events of pazopanib

Secondary Outcome Measures

Name	Time	Method
To evaluate factors that affect the blood concentration of pazopanib